ATE162550T1 - Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene - Google Patents

Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene

Info

Publication number
ATE162550T1
ATE162550T1 AT94915562T AT94915562T ATE162550T1 AT E162550 T1 ATE162550 T1 AT E162550T1 AT 94915562 T AT94915562 T AT 94915562T AT 94915562 T AT94915562 T AT 94915562T AT E162550 T1 ATE162550 T1 AT E162550T1
Authority
AT
Austria
Prior art keywords
antigens
immunogene
preventing
producing
composition
Prior art date
Application number
AT94915562T
Other languages
English (en)
Inventor
Ian Livey
Brian Crowe
Friedrich Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Application granted granted Critical
Publication of ATE162550T1 publication Critical patent/ATE162550T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT94915562T 1993-04-29 1994-04-29 Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene ATE162550T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5386393A 1993-04-29 1993-04-29

Publications (1)

Publication Number Publication Date
ATE162550T1 true ATE162550T1 (de) 1998-02-15

Family

ID=21987063

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94915562T ATE162550T1 (de) 1993-04-29 1994-04-29 Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene

Country Status (16)

Country Link
EP (1) EP0701612B1 (de)
JP (1) JPH08509371A (de)
AT (1) ATE162550T1 (de)
AU (1) AU683260B2 (de)
CA (1) CA2161534A1 (de)
CZ (1) CZ289212B6 (de)
DE (1) DE69408135T2 (de)
DK (1) DK0701612T3 (de)
ES (1) ES2114687T3 (de)
FI (1) FI955150L (de)
HR (1) HRP940279B1 (de)
HU (1) HU217024B (de)
NO (1) NO954318L (de)
PL (1) PL178775B1 (de)
SK (1) SK279968B6 (de)
WO (1) WO1994025596A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5915049A (en) * 1992-02-25 1999-06-22 Pfu Limited Binarization system for an image scanner
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ATE232212T1 (de) * 1996-05-02 2003-02-15 Dako As Verwendung von aus osp-c abgeleiteten peptidefragmenten für diagnostische methoden
US6716574B2 (en) 1996-05-02 2004-04-06 Dako A/S Osp-C derived peptide fragments
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
AT405940B (de) * 1996-06-21 1999-12-27 Immuno Ag Verfahren zur gewinnung und reinigung von rekombinantem, nicht-lipidiertem osp-protein
DE19629543C2 (de) * 1996-07-22 1999-02-11 Immuno Ag Immunassay zum Nachweis von anti-B. burgdorferi Antikörpern und Verfahren zur Serodiagnose bei Lyme Borreliose, diagnostische Mittel und Testkits zur Durchführung der Verfahren
DE19740735A1 (de) 1997-09-16 1999-03-18 Max Planck Gesellschaft Arzneimittel zur Therapie einer manifesten Lyme-Borreliose
PT1100922E (pt) 1998-07-31 2008-05-30 Gundersen Lutheran Medical Fou Utilização do(s) epítopo(s) borrelicida(s) da proteína de superfície externa c (ospc) de borrelia burgdorferi, como vacina
EP1194559B1 (de) 1999-06-18 2006-09-20 Research Foundation Of State University Of New York Gruppen von borrelia burgdorferi, die lyme krankheit verursachen
WO2002016421A2 (en) 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Altered ospa of borrelia burgdorferi
GB2414667A (en) 2004-06-03 2005-12-07 Isis Innovation Vaccine compositions of N. meningitidis PorA and FetA antigens
AU2006320246A1 (en) * 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric OspC vaccinogen and diagnostic antigen
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
CZ301244B6 (cs) * 2007-11-14 2009-12-16 Bioveta, A.S. Univerzální vakcína k lécbe a prevenci Lymeské borreliózy pro humánní a veterinární použití a zpusob její výroby
CZ301548B6 (cs) * 2008-08-20 2010-04-14 Bittner@Libor Univerzální preparát ke zvýšení obranyschopnosti, prevenci, profylaxi a lécbe Lymeské boreliózy pro humánní a veterinární použití, zpusob jeho výroby a použití
WO2025015077A1 (en) * 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221363B1 (en) * 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease

Also Published As

Publication number Publication date
NO954318D0 (no) 1995-10-27
ES2114687T3 (es) 1998-06-01
FI955150A0 (fi) 1995-10-27
WO1994025596A2 (en) 1994-11-10
CZ289212B6 (cs) 2001-12-12
NO954318L (no) 1995-12-29
EP0701612A1 (de) 1996-03-20
DE69408135D1 (de) 1998-02-26
SK279968B6 (sk) 1999-06-11
HRP940279A2 (en) 1997-10-31
CZ283995A3 (en) 1996-03-13
FI955150A7 (fi) 1995-12-28
DE69408135T2 (de) 1998-06-10
EP0701612B1 (de) 1998-01-21
FI955150L (fi) 1995-12-28
PL311301A1 (en) 1996-02-05
JPH08509371A (ja) 1996-10-08
WO1994025596A3 (en) 1994-12-22
SK134195A3 (en) 1996-05-08
HUT72923A (en) 1996-06-28
PL178775B1 (pl) 2000-06-30
CA2161534A1 (en) 1994-11-10
HU9502002D0 (en) 1995-08-28
AU683260B2 (en) 1997-11-06
DK0701612T3 (da) 1998-09-21
AU6722994A (en) 1994-11-21
HU217024B (hu) 1999-11-29
HRP940279B1 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
ATE162550T1 (de) Ospc-antigen-impfstoffe immunogene zusammensetzung zur vorbeugung und behandlung von lyme-krankheit und rekombinante verfahren zur herstellung von derartige antigene
YU49370B (sh) Postupak za pripremanje vakcine protiv lajmske bolesti
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
CY1111831T1 (el) Παραγωγα ογκο-συναφους αντιγονου απο την οικογενεια mage και αλληλουχιες νουκλεϊνικου οξεος που κωδικοποιουν αυτα, που χρησιμοποιουνται για την παρασκευη πρωτεϊνων συντηξης και συνθεσεων για εμβολιασμο
DE69536091D1 (de) Immunisierung durch Impfung von DNS Transkriptionseinheit
DE69618601D1 (de) Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa)
DK0555276T3 (da) Immunogene komplekser, især iscomer
DK0726955T3 (da) Kimære proteiner, som omfatter Borreliapolypeptider, og anvendelser heraf
ATE126594T1 (de) Verfahren zur herstellung des hochmolekulargewichtigen zell-verbundenen proteins von campylobakter pylori und seine verwendung zum serologischen nachweis von campylobakter pylori-infektionen.
FR2832410B1 (fr) Antigene mycobacterien recombinant de type hemagglutinine de liaison a l'heparine methylee, procedes de preparation et compositions immunogenes comprenant un tel antigene
DE69018926D1 (de) Vakzine gegen Bordetella.
DE69737323D1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
DE68904617D1 (de) Jodhaltige polymere mit skeletten von dextran, verfahren zu ihrer herstellung und ihre verwendungen als kontrastmittel.
CA1272124C (en) Marginal Anaplasma Subunit Antigen for Vaccination and Diagnostic Purposes
DK218886D0 (da) Tvaerreaktive og beskyttende epitoper af circumsporozoit-proteiner
NO942707L (no) Syntetiske peptider egnet for vaksine mot rubellsinfeksjoner
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
DE69224590D1 (de) Hepatitis a virusstamm, verfahren zur isolierung dieses stammes und hepatitis a vakzine
DK0809653T3 (da) Helicobacter pylori-antigen
DE69119230D1 (de) Schützende antikörper erregende plasmodium falciparum antigene und deren verwendung in impfstoffen
AT384363B (de) Verfahren zur verwendung von antigenreaktiven peptiden zur herstellung von gegen fsme-virusinfektionen wirksamen vakzinen
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee